AusCann Group Holdings Ltd Stock price

Equities

AC8

AU000000AC89

Pharmaceuticals

Market Closed - Australian S.E. 02:10:35 2022-08-31 am EDT 5-day change 1st Jan Change
0.04 AUD -4.76% Intraday chart for AusCann Group Holdings Ltd -.--% -.--%
Sales 2022 2.04M 1.33M Sales 2023 1.55M 1.01M Capitalization 17.62M 11.48M
Net income 2022 -26M -16.94M Net income 2023 -10M -6.51M EV / Sales 2022 5.19 x
Net cash position 2022 5.72M 3.73M Net cash position 2023 7.3M 4.75M EV / Sales 2023 6.66 x
P/E ratio 2022
-0.62 x
P/E ratio 2023
-1.61 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 72.13%
More Fundamentals * Assessed data
Dynamic Chart
3 years
0.04
Extreme 0.035
0.15
5 years
0.04
Extreme 0.035
0.53
10 years
0.04
Extreme 0.035
1.86
More quotes
Managers TitleAgeSince
Director of Finance/CFO - 19-11-30
Members of the board TitleAgeSince
Director/Board Member 53 23-06-28
Director of Finance/CFO - 19-11-30
Chairman - Nov. 30
More insiders
AusCann Group Holdings Limited is an Australia-based company focused on the development and commercialization of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. Its products include Neuvis, CPAT-01, DermaCann and MicroMax. CPAT-01 is a liquid, oral veterinary medicine containing standardized tetrahydrocannabinol (THC) and cannabinoids (CBD) whole plant extracts in a proprietary ratio to target pain and inflammation in dogs. DermaCann is a CBD-derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. The product is a liquid oral oil formulation containing CBD in a patented combination with other bioactive lipids designed to target inflammation and immune modulation pathways. MicroMAX is an encapsulation technology for use in the field of animal therapeutics. Its subsidiaries include AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited.
More about the company
  1. Stock
  2. Equities
  3. Stock AusCann Group Holdings Ltd - Australian S.E.